Abbisko Cayman Limited (HKG:2256)

Market Cap	7.59B -33.9%
Revenue (ttm)	681.17M +21.5%
Net Income	61.48M +95.2%
EPS	0.10 +121.1%
Shares Out	716.46M
PE Ratio	107.70
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,677,000
Open	10.45
Previous Close	10.20
Day's Range	10.45 - 10.88
52-Week Range	8.34 - 19.78
Beta	1.20
Analysts	Strong Buy
Price Target	21.74 (+105.09%)
Earnings Date	Aug 24, 2026

About Abbisko Cayman

Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 276
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2256

Financial Performance

In 2025, Abbisko Cayman's revenue was 612.12 million, an increase of 21.45% compared to the previous year's 503.99 million. Earnings were 55.25 million, an increase of 95.21%.

Financial numbers in CNY

Analyst Summary

According to 8 analysts, the average rating for 2256 stock is "Strong Buy." The 12-month stock price target is $21.74, which is an increase of 105.09% from the latest price.

Price Target

$21.74

(105.09% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 20, 2026

Data Sources Report a data error